A characteristic of GPCRs in the G protein-coupled state is that the affinity of the agonist often increases significantly, but the molecular basis for this is unclear. We have determined six active-state structures of the β 1 -adrenoceptor (β 1 AR) bound to conformation-specific nanobodies in the presence of agonists of varying efficacy. A direct comparison with structures of β 1 AR in inactive states bound to the identical ligands showed a 24-42% reduction in the volume of the orthosteric binding site. Potential hydrogen bonds were also shorter, and there was up to a 30% increase in the number of atomic contacts between the receptor and ligand. GPCRs are highly conserved, so these factors will likely be essential in increasing the affinity of a wide range of structurally distinct agonists.
One Sentence Summary: High affinity agonist binding to G protein-coupled GPCRs results from an increase in the number and strength of protein-ligand interactions.
Main Text:
GPCRs exist in an ensemble of conformations that can be selectively stabilized by the binding of a ligand and through interactions with signaling molecules such as G proteins (1, 2) . The evidence for this comes from a wealth of pharmacological, biophysical and structural data. Pharmacology has characterized at least two distinct states of GPCRs, a conformation with high affinity for agonists when coupled to G proteins and a conformation with low affinity for agonists in the absence of G proteins (1) , although a plethora of sub-states can also exist between these two extremes (3, 4) .
Fluorescence studies (4, 5) and 19 F-NMR (6, 7) show that receptors in the absence of ligands can access many of these conformational states and that addition of an inverse agonist stabilizes a different state from an agonist or partial agonist. However, the fully active state can only be stabilized through coupling of a G protein or a G protein mimetic such as a conformation-specific nanobody (8) . When GPCRs are stabilized in the fully active state, they typically show an increased affinity for the agonist, which can be as high as 100-fold, and has been observed in diverse receptors such as β 2adrenoceptors (9) , the adenosine A 2A receptor (10) , the muscarinic M2 receptor (11) and the µ-opioid receptor (12) . In addition, the magnitude of the agonist affinity shift is dependent upon the structure of the ligand (9) , although the molecular basis for this is unknown. Circumstantial evidence suggests that a decrease in the volume of the ligand binding pocket may be important during GPCR activation, although the exact nature of any effect is unclear because all previous comparisons have either been between different GPCRs (13) or between the same receptor but bound to ligands of different size and structures (14) . Another proposal is that occlusion of the orthosteric biding site is the main cause for the increase in agonist affinity (15) . There is thus currently no direct comparison between structures of a single receptor in the inactive state and the fully active state bound to the same ligand.
The majority of GPCR structures have been determined in an inactive state and these are highly conserved (16) . A number of GPCR structures have also been determined in a fully active state coupled to either a G protein or a conformationspecific nanobody, revealing a conserved mechanism for GPCR activation (17). In addition, a number of structures have been determined of intermediate states (18) , with agonists bound to receptors in the absence of a G protein or nanobody. In all these latter cases, the receptors are not in a fully active state and fall into two main classes, an active-like state or an inactive-like state. The active-like state is best characterised for the adenosine A 2A receptor (19, 20) , where comparison with the G protein-coupled state (10) shows that full receptor activation is accompanied by the outward movement of H6 and the rotamer changes of Arg 3.50 Tyr 5.58 and Tyr 7.53 (superscripts are the Ballesteros-Weinstein numbers (21) ). Notably, there is no significant change in the structure of the orthosteric binding site (10) . In contrast, structures of β-adrenoceptors bound to agonists (22, 23) are virtually identical to the inactive state bound to antagonists, except for a ~1 Å contraction of the orthosteric binding site and a rotamer change of Ser 5.46 . Previously we determined the structures of β 1 AR in an inactive state bound to agonists and partial agonists (22, 24) and this provides an ideal system for studying the molecular basis for agonists affinity shifts in GPCRs. We have therefore determined structures of β 1 AR in the active state coupled to a conformation-specific nanobody (either Nb80 or Nb6B9) used previously to crystallise β 2 AR in an active state coupled to agonists (13, 25) .
Six crystal structures with overall resolutions between 2.9 Å -3.2 Å (Table S1) were determined of β 1 AR bound to either Nb80 or Nb6B9, and the overall structures were all virtually identical ( Fig. 1 ; 0.2-0.3 Å RMSD for Cα atoms). Structures were determined bound to full agonists (isoprenaline, formoterol), partial agonists (salbutamol, dobutamine, xamoterol) and a weak partial agonist formerly described as an antagonist (cyanopindolol). All the agonists and partial agonists showed an increase in affinity when β 1 AR was coupled to the engineered G protein mini-G s , whereas cyanopindolol bound with similar high affinity in both the presence and absence of mini-G s (Fig. 1 ). The inability of mini-G s to increase the affinity of cyanopindolol was not a consequence of the oxymethylene spacer between the ethanolamine backbone and ligand head group that prevents contraction of the ligandbinding pocket in β 1 AR antagonists, because this is also found in the partial agonist xamoterol. The overall structure of the β 1 AR-nanobody complexes bound to either agonists or partial agonists is virtually identical to that of the agonist-bound Nb6B9β 2 AR complex (0.5 Å RMSD of 1601 Cα atoms) and the overall conformational changes compared to the inactive state are consequently very similar (Fig. 2 ). These are characterised by an outward movement of the cytoplasmic ends of H5 and H6 and an inward movement of H7. In contrast, the extracellular ends of H6 and H7 move inwards, with sideways movements of the extracellular ends of H1 and H2 and an inwards movement of ECL2. These changes result in the partial occlusion of the orthosteric binding pocket (Fig. 2) , which is consistent with observations on nanobody-bound β 2 AR (13, 25) .
Detailed comparisons were made between the inactive state structures of β 1 AR bound to either isoprenaline, salbutamol, dobutamine or cyanopindolol with the respective active state structures (Figs. 3 and 4) . In all cases, there was a decrease in the volume of the orthosteric binding site that varied depending on the ligand (Fig.   S1 ). The largest decrease was observed for the full agonist isoprenaline and the smallest decrease was observed for the weak partial agonist cyanopindolol (volume reductions: isoprenaline, 42%, dobutamine, 30%; salbutamol, 30%; cyanopindolol, 24%). The decrease in the volume of the orthosteric binding site when isoprenaline was bound was due primarily to the inward movement of the extracellular ends of H6 and H7, an inward movement and an increase in the H5 bulge at Ser215 5.46 and the reorientation of residues Phe201 ECL2 and Phe325 7.35 . The magnitude of these changes correlated with efficacy: thus the structure with cyanopindolol bound showed little change at the extracellular side of H7 (0.9 Å shift when cyanopindolol was bound compared to 3.7 Å when isoprenaline was bound; measurement at the Cα of Asp322 7.32 ) and less change in the bulge of H5 (2.0 Å shift when cyanopindolol was bound compared to 3.4 Å when isoprenaline was bound; measurement at Cα of Ser215 5.46 ). The pincer-like movement of Phe201 ECL2 and Phe325 7.35 towards the ligand has the largest effect on reducing the volume of the orthosteric binding pocket, with the maximal shift observed in the isoprenaline structure of 3.1 Å for Phe201 ECL2 and 2.5 Å for Phe325 7.35 (measured at the CZ atom of the side chain). The movement of Phe201 ECL2 appeared to correlate with the ligand structure because in all cases it formed van der Waals contacts with the ligand. In contrast, Phe325 7.35 was not within van der Waals contact with any of the four ligands and moved as a consequence of the inward tilt of H7. 6 The reduction in the volume of the orthosteric binding pocket correlated with an overall reduction in the average distance between atoms in the ligand and receptor by 0.1-0.3 Å. Although amino acid residues in H3, H5, H6, H7 and ECL2 (and H2 for dobutamine) were all involved in contributing to ligand-receptor contacts, the biggest decreases in contact distance were ligand dependent (Fig 4) . The greatest decreases in ligand-receptor distances were observed between Asp121 3.32 and salbutamol, Gly98 2.61 and dobutamine, and Val125 3.36 and cyanopindol, where the residues were all greater than 1 Å closer to the ligand in the active state. However, the changes around H5 and H6 may lead to greater changes in affinity as these involved the strengthening of hydrogen bonds. For example, Asn310 6.55 was predicted to make a weak hydrogen bond to the para-hydroxyl group of isoprenaline (3.5 Å between donor and acceptor) in the inactive state, which changes to 2.8 Å in the active state. In contrast, hydrogen bonds formed by Ser211 5.42 and Ser215 5.46 do not alter length significantly. This differed to observations for dobutamine and salbutamol where the hydrogen bond to Ser215 5.46 was 0.8 Å shorter for both ligands and the hydrogen bond to Ser211 5.42 also shortened by 0.7 Å to salbutamol, but remained unchanged to dobutamine. Most of the observed differences are due to the contraction of the binding pocket, but the significant shortening of the hydrogen bond between Ser211 5.42 and salbutamol is due to a rotamer change.
There were also notable increases in the number of ligand-receptor contacts made by Phe201 ECL2 to cyanopindol and Asp121 3.32 to salbutamol that were not observed at the respective positions with the other ligands ( Fig. S2 ). Thus, although all the ligand binding pockets contracted upon receptor activation, the changes in ligand-receptor contacts were not conserved, despite the similarity in chemotypes amongst the four ligands studied. In addition, there was no clear correlation between the number and type of ligand-receptor interactions present and either the magnitude of ligand affinity increase on receptor activation or the decrease in volume of the orthosteric binding site. It was particularly notable that cyanopindolol bound to β 1 AR with similar affinity in both the presence and absence of a coupled G protein despite the contraction of the binding pocket and increase in receptor ligand contacts upon activation. This may be a consequence of constraints on the possible conformation change imposed by the rigidity of cyanopindol that prevents the full contraction of the ligand binding pocket by preventing the movement of H7 and the bulge in H5 that are observed in the other structures ( Fig. S1 ).
Previous structural studies on β 1 AR suggested that the mode of ligand interaction with Ser215 5.46 in an inactive state correlates with efficacy by affecting the likelihood of transitions to activated states (22, 26) . The active state structures determined here suggest that the ability of ligands to stabilize the activated state must also be taken into account when considering ligand efficacy. For example, the weak partial agonists cyanopindolol and xamoterol do not allow the full contraction of the ligand binding pocket observed with isoprenaline or formoterol. In contrast, the partial agonists salbutamol and dobutamine show similarly contracted binding pockets to isoprenaline and formoterol, but do not engage Ser215 5.46 in the inactive state like full agonists (22) .
The role of the partial occlusion of the orthosteric binding site upon activation of β 1 AR was tested by mutagenesis inspired from the active state structure of β 2 AR (13, 25) . In β 2 AR, it was proposed that the occlusion of the binding site was a significant factor in increasing agonist affinity upon G protein coupling (15) . In particular, Tyr308 7.35 was within van der Waals distance of Phe193 ECL2 on the opposite side of the entrance to the orthosteric binding pocket and had a major effect on decreasing the rates of association and dissociation of ligands in the active state compared to the inactive state. The β 2 AR residues Phe193 ECL2 /Tyr308 7.35 are equivalent to Phe201 ECL2 /Phe325 7.35 in β 1 AR where they are not in van der Waals contact and therefore do not occlude significantly the entrance to the binding pocket as observed in β 2 AR ( Fig. 5 ). Thus the mutation F325Y 7.35 in β 1 AR was predicted to occlude the entrance to the orthosteric binding pocket and decrease the rate of ligand association, and conversely, F325A 7.35 was predicted to make the entrance wider and increase the rate of ligand association. When the initial rate of 3 H-dihydroalprenolol for the inactive states of β 1 AR and β 1 AR(F325Y) showed a large decrease in affinities for norepinephrine (5.8 fold), epinephrine (10.5-fold) and isoprenaline (6.5-fold), which implied that the greater agonist affinity shift observed in β 1 AR(F325Y) compared to β 1 AR was due to destabilisation of the inactive state and not stabilisation of the active state. This suggested that partial occlusion of the ligand binding pocket in β 1 AR(F325Y) during formation of the active state played little role in the increase of agonist affinity on G protein coupling.
The destabilising effect of the F325Y mutation in β 1 AR on the agonist-bound inactive state suggested that converting the extracellular surface of β 2 AR to make it similar to β 1 AR would increase the affinity of the inactive state and leave the affinity of the G protein-coupled activated state approximately unchanged. The β 2 AR mutant constructed, β 2 AR(β 1 LBP), did indeed show these characteristics ( Fig 5; see Methods for the rationale of the four mutations used: Y174W ECL2 , H296N 6.58 , K305D 7.32 and Y308F 7.35 ). In addition, the accessibility of the β 1 AR orthosteric binding pocket in the G protein-coupled state to 125 I-cyanopindolol was greater than that observed for β 2 AR (Fig. S3 ). The four mutations in β 2 AR(β 1 LBP) converted the behaviour of β 2 AR to that of β 1 AR. Adding the converse residues from β 2 AR into β 1 AR, to make the mutant β 1 AR(β 2 LBP), converted the accessibility of the orthosteric binding site in β 1 AR to that of β 2 AR (Fig. S3 ).
The multiple structures of β 1 AR in the activated state bound to ligands of different efficacy defined major contributors towards the increase in agonist affinity upon G protein coupling. The orthosteric binding pocket decreased in volume, regardless of the efficacy of the ligand bound. In addition, there were more ligandreceptor contacts and/or interactions of greater strength due to shortening of the contacts involved. Partial occlusion of the entrance to the receptor binding pocket was excluded as a potential factor that affected the change in agonist affinity on G protein coupling, although it was clearly a factor in changing the kinetics of ligand association. A purely steric effect would not be expected to affect ligand affinity, given that this is the ratio between the association and dissociation constants, but it is apparent from mutagenesis data that mutations of key residues in the entrance to the orthosteric binding site preferentially affected the agonist affinity of the inactive state, and hence altered the agonist affinity shift upon G protein coupling. A key finding of this work was that the increase in agonist affinity upon G protein coupling arose from changes at different amino acid residues in different areas of the orthosteric binding pocket. This has implications for drug development as structure-based drug design usually considers only a single state, despite the fact that any drug will actually experience multiple different states of a GPCR. In the absence of crystal structures of multiple states of most receptors with multiple different ligands, the insights into how ligands bind to both the inactive and active states of β 1 AR will help in developing tools for engineering efficacy into ligands at an early stage in drug development. As GPCRs are highly conserved, these conclusions are likely to be applicable to many different receptors.
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Materials and Methods
Cloning, expression and purification of β 1 AR. The turkey (Meleagris gallopavo) β 1 AR construct trx-β 1 AR (22) used for crystallization of the β 1 AR-nanobody complexes was based on β44-m23, with the same truncations and deletions, but only four thermostabilizing mutations, R68S 1.59 , M90V 2.53 , F327A 7.37 and F338M 7.48 . The mutations Y227A 5.58 and A282L 6.27 on H5 and H6 were removed, because the reversion of these two mutations was sufficient to enable full activation and high affinity agonist binding in the presence of G proteins and nanobody Nb80 (27) . A thioredoxin (E. coli trxA, with mutations C32S & C35S) fusion was attached via the linker EAAAK at the N-terminus of β 1 AR. The construct was cloned into the baculovirus transfer vector pAcGP67B (BD Biosciences) and the recombinant baculovirus was generated by co-
transfection of insect cells with BacPAK6 linearized baculovirus DNA (Oxford Expression
Technologies Ltd). Plaque purified virus was used to express receptors in High Five cells (ThermoFisher Scientific) grown in ESF921 (Expression Systems) supplemented with 5% heatinactivated foetal bovine serum (Sigma) as described previously (28).
The membrane fraction was prepared, and the receptor was solubilized in 1.5% decylmaltoside (DM, Generon) and further purified in 0.1% DM by Ni 2+ -affinity chromatography and alprenolol sepharose chromatography, with elution from the alprenolol sepharose ligand affinity column as described previously (22, 28, 29) with 100 µM of the appropriate ligand for complex formation, concentrated to 15-25 mg/ml and either used directly for the formation of complexes, or frozen for later use. Radioligand binding studies on βARs and mutants. Wild type turkey β 1 AR, human β 1 AR and human β 2 AR, and mutants of these receptors, were all expressed using recombinant baculoviruses in insect cells for radioligand binding studies. Amino acid residues close to the ligand binding pocket (LBP) which differ between β 1 AR and β 2 AR were mutated to compare some of the pharmacological characteristics of the different receptor subtypes. The residues selected for mutation were Trp182 ECL2 , Asn313 6.58 , Asp322 7.32 and Phe325 7.35 (β 1 AR), equivalent to Tyr174 ECL2 , His296 6.58 , Lys305 7.32 and Tyr308 7.35 (β 2 AR). The first residues, Trp182 ECL2 /Tyr174 ECL2 (β 1 AR/β 2 AR) was chosen because they are involved in differing modes of interaction with Phe201 ECL2 /Phe193 ECL2 that were observed in comparisons of crystal structures, as well as possible involvement in a secondary affinity state observed in β 1 AR but not β 2 AR(41). The latter three pairs of residues were chosen because His296 6.58 , Lys305 7.32 and Tyr308 7.35 have all been suggested to contribute to high affinity binding of agonist to β 2 AR in the presence of G protein (13, 15) . For further explanation see Fig S6. The initial turkey β 1 AR construct was based on the β44-m23 construct (22) , but without any of the stabilizing mutations. Two variants of β 1 AR were prepared with mutations of amino acids in the ligand binding pocket (LBP) that were intended to make the β 1 AR similar to the β 2 AR. These were β 1 AR(F325Y) (mutation F325Y 7.35 ) and β 1 AR(β 2 LBP) that contained following mutations: W182Y ECL2 , N313H 6.58 , D322K 7.32 , F325Y 7.35 . The human β 2 AR was mutated to generate the construct β 2 AR(β 1 LBP) that contained the mutations Y174W ECL2 , H296N 6.58 , K305E 7.32 and Y308F 7.35 . Mutants were constructed in the baculovirus transfer vectors pBacPAK8 (Clontech) for β 1 AR and pAcGP67B (BD Biosciences) for β 2 AR(β 1 LBP) by using Quikchange protocols (Stratagene) with KOD polymerase (EMD Millipore), and were 7 expressed in insect cells after co-transfection with linearized baculovirus as previously described.
Crude insect cell membrane fractions were prepared by resuspending cell pellets from 1 ml culture volume in 1 ml of assay buffer (20 mM Hepes-NaOH pH7.5, 50 mM NaCl, 2.5 mM MgCl 2 , 0.1% BSA) to give final concentrations of 1-3 x 10 6 cells/ml. Cells were sheared by 10 passages through a bent 26G needle and cell debris was removed by centrifugation (1500 xg, 2 min) and the supernatants were diluted in assay buffer for radioligand binding studies.
Saturation binding assay to determine affinities for depending on the apparent K D determined for the construct with and without G protein (see Table S3 ), so that concentrations of competing ligand were in the range 1-2.5 x K D ). Samples were incubated at 20°C for 1-5 h (longer incubation times were required for the wild-type β 2 AR to allow equilibration with DHA), before filtering through 96-well fibre filter plates as previously described. Radioligand binding was quantified by scintillation counting and K i values were determined using GraphPad Prism version 7.0b. All K i values obtained are given in Tables   S2 and S3 and are mean values obtained from at least two experiments performed in duplicate.
Racemic mixtures of the tested ligands were used in all cases apart from measurements with epinephrine and norepinephrine where the active (R-) enantiomers were used, and also In each panel β 1 AR is shown as a cartoon (inactive state, grey; active state, rainbow coloration, N-terminus blue, C-terminus red). The volume of the inactive state is outlined as a mesh and the volume of the active state is outlined as a solid surface. Views on the left are from the extracellular surface and the views on the right are parallel to the membrane plane Tables S2 and S3 . All experiments were performed in duplicate. Experiments to determine the high affinity state were performed in a molar excess of mini-G s (see methods); red curves, low affinity state; blue curves, high affinity state.
Fig. S5. Formation of complexes between trx-β 1 AR and mini-G s in the presence of isoprenaline or
cyanopindolol. Complexes were formed as described in the Methods section in the presence of either the full agonist isoprenaline or the weak partial agonist cyanopindolol. The components were then resolved by SEC and the fractions analysed by Coomassie blue-stained SDS-PAGE.
Fig. S6.
Comparison of β 1 AR and β 2 AR structures: subtype-specific differences imply rationale for mutagenesis. Comparison of structures of (a) activated β 1 AR with isoprenaline bound and (b) β 2 AR with adrenaline bound (4LDO). In β 1 AR, F201 interacts with W182 on ECL2, and not F325 on H7, in the β 2 AR F193 interacts with Y308 on H7, but not with Y174 on ECL2. This subtype specific difference in interactions between F201 (β 1 AR) and F193 (β 2 AR) can be observed in most structures with the exception of β 2 AR crystallized with ligands with bulky headgroups, where interactions between F193 and Y174 can be observed. Alternative views of activated β 1 AR with isoprenaline bound (c) and (d) β 2 AR with adrenaline bound (4LDO) with ECL2 removed for clarity, residues that differ between the two receptors are labeled in red. In the β 2 AR, all of these have been suggested as being involved in high affinity agonist binding states. In the case of H296, this is by participation in an extended H-bond network that also includes T195 on ECL2 (not shown). 
